Details

Autor(en) / Beteiligte

• Camera, Silvia
• Telli, Tugba Akin
• Woff, Erwin
• Vandeputte, Caroline
• Kehagias, Pashalina
• Guiot, Thomas
• Critchi, Gabriela
• Wissam, Yacine
• Bregni, Giacomo
• Trevisi, Elena
• Pretta, Andrea
• Senti, Chiara
• Leduc, Sophia
• Gkolfakis, Paraskevas
• Hoerner, Frederic
• Rothe, Francoise
• Sclafani, Francesco
• Flamen, Patrick
• Deleporte, Amelie
• Hendlisz, Alain

Titel

Prognostic Value of the Pace of Tumor Progression as Assessed by Serial [.sup.18]F-FDG PET/CT Scan and Liquid Biopsy in Refractory Colorectal Cancer: The CORIOLAN Trial

Ist Teil von

• Cancers, 2020-10, Vol.12 (10), p.1

Ort / Verlag

MDPI AG

Erscheinungsjahr

2020

Quelle

EZB Electronic Journals Library

Beschreibungen/Notizen

• Management of chemorefractory colorectal cancer patient is challenging, and reliable tools which can predict individual patient prognosis and help the decision making are needed. In this study, we hypothesized that the natural pace of cancer growth and progression, as assessed by early changes of a number of imaging and circulating biomarkers which are surrogates of tumor burden (i.e., metabolically active tumor volume, carcinoembryonic antigen, circulating tumor cells and circulating tumor DNA), could predict patient prognosis. By prospectively recruiting 47 eligible patients who had measurements of these biomarkers taken two weeks apart in the absence of any active anti-cancer treatment, we failed to demonstrate our hypothesis. On the other hand, we found that baseline assessment of the same biomarkers was associated with survival outcomes. Larger studies are needed to confirm these findings and translate them into applications for clinical practice.